Fujifilm expands gene therapy analytical services with $55m lab

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/undefined)
(Image: Getty/undefined)

Related tags: Fujifilm diosynth biotechnologies, Cell therapy, cell and gene therapy, Gene therapy, Process analytical technology

Fujifilm Diosynth opens a 60,000-square-feet Gene Therapy Innovation Center to support upstream, downstream and analytical development services.

The laboratory space will be added to Fujifilm Diosynth Biotechnologies (FDB) gene therapy manufacturing facility in Texas, US, and is expected to boost the company’s offering of process and analytical development services for gene therapies developers.

The establishment of the laboratory space, which will cost the company $55m (€49.65m), is part of a total investment of ¥13bn ($120m) made by Fujifilm Corporation, as part of the company’s effort to meet the growing demands of the market.

“We need to invest now, in technology, assets and people,” ​commented Martin Meeson, president and COO of FDB for the US, adding that the company is ‘very much aware’ of the gene therapy market’s ‘incredible’ growth.

The facility is expected to be operational in the fall of 2021 and will add approximately 100 jobs to the company’s College Station campus in Texas.

FDB’s 80,000-square-feet plant in Texas opened early last year​, with the company looking to tap into the booming cell and gene therapies space, and provide clinical and commercial manufacturing capabilities for developers.

Earlier this year, Meeson told us that the increase of assets has led the company to establish new partnerships, with interest continuously rising, and mentioned that, at that point, the Texas facility was ‘easily expandable’ to help the company answer such demand.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars